Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNMX NASDAQ:IPSC NASDAQ:OTLK NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNMXAevi Genomic Medicine$0.17$0.17$0.11▼$0.35$12.89M1.133.16 million shs2.95 million shsIPSCCentury Therapeutics$0.58+0.1%$0.57$0.34▼$2.55$50.04M1.78580,755 shs639,676 shsOTLKOncobiologics$2.18-5.6%$1.82$0.87▼$8.70$73.18M0.25862,995 shs860,975 shsSTROSutro Biopharma$0.76-0.8%$0.82$0.52▼$5.17$64.19M1.641.12 million shs205,689 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNMXAevi Genomic Medicine0.00%0.00%0.00%0.00%0.00%IPSCCentury Therapeutics0.00%-3.25%-0.95%+6.82%-80.64%OTLKOncobiologics0.00%+5.31%+29.76%+50.34%-75.64%STROSutro Biopharma0.00%-0.20%-4.26%+43.94%-81.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNMXAevi Genomic MedicineN/AN/AN/AN/AN/AN/AN/AN/AIPSCCentury Therapeutics3.2933 of 5 stars3.55.00.00.02.41.70.6OTLKOncobiologics1.8995 of 5 stars3.44.00.00.00.60.00.6STROSutro Biopharma4.1524 of 5 stars3.15.00.04.72.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNMXAevi Genomic Medicine 0.00N/AN/AN/AIPSCCentury Therapeutics 3.00Buy$4.20623.14% UpsideOTLKOncobiologics 2.80Moderate Buy$9.60340.37% UpsideSTROSutro Biopharma 2.25Hold$6.11704.51% UpsideCurrent Analyst Ratings BreakdownLatest GNMX, OTLK, STRO, and IPSC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$2.006/6/2025OTLKOncobiologicsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $21.005/20/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/19/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.805/16/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.004/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNMXAevi Genomic MedicineN/AN/AN/AN/A$0.12 per shareN/AIPSCCentury Therapeutics$6.59M7.59N/AN/A$1.90 per share0.31OTLKOncobiologicsN/AN/AN/AN/A($3.09) per shareN/ASTROSutro Biopharma$62.04M1.03N/AN/A$0.54 per share1.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNMXAevi Genomic Medicine-$30.77M-$0.50N/A∞N/AN/A-898.31%-286.73%N/AIPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-10.71%-5.96%8/14/2025 (Estimated)OTLKOncobiologics-$75.37M-$0.91N/AN/AN/AN/AN/A-271.12%8/13/2025 (Estimated)STROSutro Biopharma-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)Latest GNMX, OTLK, STRO, and IPSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IPSCCentury Therapeutics-$0.38N/AN/AN/AN/AN/A8/13/2025Q3 2025OTLKOncobiologics-$0.42N/AN/AN/A$1.66 millionN/A8/12/2025Q2 2025STROSutro Biopharma-$0.53N/AN/AN/A$14.55 millionN/A5/15/2025Q1 2025IPSCCentury Therapeutics-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million5/15/2025Q2 2025OTLKOncobiologics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A5/8/2025Q1 2025STROSutro Biopharma-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNMXAevi Genomic MedicineN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNMXAevi Genomic MedicineN/A0.650.65IPSCCentury TherapeuticsN/A11.7011.70OTLKOncobiologicsN/A0.720.57STROSutro BiopharmaN/A2.162.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNMXAevi Genomic Medicine7.03%IPSCCentury Therapeutics50.20%OTLKOncobiologics11.20%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipGNMXAevi Genomic Medicine43.80%IPSCCentury Therapeutics5.00%OTLKOncobiologics4.80%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNMXAevi Genomic Medicine1477.71 millionN/AOptionableIPSCCentury Therapeutics17086.16 million81.85 millionOptionableOTLKOncobiologics2033.57 million31.96 millionOptionableSTROSutro Biopharma24084.46 million81.42 millionOptionableGNMX, OTLK, STRO, and IPSC HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Hold" from BrokeragesJuly 11, 2025 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from BrokeragesJuly 11, 2025 | marketbeat.comSutro Biopharma upgraded to Overweight from Neutral at Piper SandlerJune 16, 2025 | msn.comSutro Biopharma Appoints Greg Chow as Chief Financial OfficerJune 2, 2025 | finance.yahoo.comSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deSutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comSutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | globenewswire.comSutro Biopharma to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%April 26, 2025 | aaii.comAWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%April 1, 2025 | aaii.comAWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%March 18, 2025 | aaii.comASutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comSutro Biopharma presents expanded data from REFRalphaME-01 trialMarch 16, 2025 | markets.businessinsider.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | globenewswire.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 35.19%March 15, 2025 | aaii.comAWedbush Downgrades Sutro Biopharma (STRO)March 15, 2025 | msn.comSutro Biopharma downgraded to Neutral from Overweight at Piper SandlerMarch 14, 2025 | markets.businessinsider.comSutro Cuts Half of Staff, Deprioritizes ADC in Strategic ReviewMarch 14, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not Hype3 Catalysts Driving Plug Power’s Turnaround CaseBy Jeffrey Neal Johnson | July 18, 2025View 3 Catalysts Driving Plug Power’s Turnaround CaseTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffGNMX, OTLK, STRO, and IPSC Company DescriptionsAevi Genomic Medicine NASDAQ:GNMXAevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.Century Therapeutics NASDAQ:IPSC$0.58 +0.00 (+0.10%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.59 +0.01 (+2.10%) As of 07/18/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Oncobiologics NASDAQ:OTLK$2.18 -0.13 (-5.63%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.22 +0.04 (+2.06%) As of 07/18/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Sutro Biopharma NASDAQ:STRO$0.76 -0.01 (-0.77%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.77 +0.01 (+1.18%) As of 07/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.